Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space.
Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources.
NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration.
Valneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®.
Tubulis GmbHTubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.
The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.
French dairy giant Danone, engineering materials group Michelin, US start-up DMC Biotechnologies and Crédit Agricole Centre France have joined forces to create the Biotech Open Platform as precision fermentation centre.
German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models.
Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.